Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Survodutide — internal code BI 456906 — is a synthetic peptide that activates both the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is structurally derived from glucagon and engineered with a fatty acid albumin-binding side chain that extends its circulating half-life to approximately one week, enabling once-weekly subcutaneous dosing.
The compound was discovered by Zealand Pharma and licensed to Boehringer Ingelheim, which is leading the clinical program.
History
Boehringer Ingelheim disclosed BI 456906's chemistry and Phase I data in 2022. The Phase II obesity dose-finding trial (le Roux et al., Lancet Diabetes Endocrinol 2024) randomized 387 adults to placebo or one of four survodutide doses (0.6, 2.4, 3.6, or 4.8 mg weekly) over 46 weeks of treatment. At the highest dose, the mean body weight reduction was 14.9% versus 2.8% on placebo.
A separate Phase II trial in type 2 diabetes (Blüher et al., Diabetologia 2024) reported HbA1c reductions of approximately 1.8 percentage points at the top dose, similar to semaglutide 1.0 mg in the same trial. A 2024 Phase II MASH trial (Sanyal et al., NEJM) reported histological MASH resolution without fibrosis worsening in 47% to 83% of participants on the higher doses versus 14% on placebo over 48 weeks.
These results led to FDA Breakthrough Therapy designation for MASH in February 2024 and the launch of the SYNCHRONIZE Phase III obesity program. Phase III MASH and cardiovascular outcomes trials are also underway.
Regulatory status
Survodutide is not approved anywhere. It is available only through registered clinical trials. There is no legitimate compounded supply. The FDA Breakthrough designation accelerates review but does not constitute approval.
Mechanism
The dual receptor approach is designed to combine the established appetite and glucose effects of GLP-1 agonism with the energy-expenditure and hepatic-fat effects of glucagon agonism. The published mechanism papers describe complementary effects:
- GLP-1 receptor activation drives glucose-dependent insulin release, glucagon suppression in the islet context, slowed gastric emptying, and central appetite reduction.
- Glucagon receptor activation raises resting energy expenditure, promotes hepatic fat oxidation, and increases lipolysis in adipose tissue. The glucose-raising effect of pure glucagon is offset by the simultaneous GLP-1 stimulation.
The glucagon arm is the proposed reason for survodutide's strong effects on liver fat in the MASH trial, where reductions in liver fat content exceeded 75% in many participants on the higher doses.
Half-life and dosing intervals
The published half-life is approximately 7 days, supporting once-weekly subcutaneous injection. Steady state is reached after roughly 5 to 6 weeks.
In the Phase II obesity trial, doses were escalated every 2 weeks over a 20-week period to manage gastrointestinal side effects. The escalation for the 4.8 mg target dose stepped through 0.3, 0.6, 0.9, 1.2, 1.8, 2.4, 3.0, 3.6, and 4.8 mg. Slower escalation reduced the rate of nausea and vomiting but did not eliminate it.
Reconstitution example
Research-grade survodutide is typically supplied lyophilized in 5 mg or 10 mg vials.
A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. On a 1 mL U-100 insulin syringe, 6 units (0.06 mL) contains 0.3 mg — the lowest step used in the Phase II escalation. Vial's calculator handles unit-to-mg conversion automatically.
What to know
- Investigational only. Phase III data is not expected before 2026–2027 for the obesity indication. No regulator has reviewed the full safety package.
- Dose-dependent GI events. Phase II reported nausea, vomiting, and diarrhea in roughly 75% of participants on the higher doses, with most events concentrated during escalation.
- MASH signal. Survodutide is one of several incretin-class compounds showing strong liver-fat reduction; the histological response rate in the Phase II MASH trial is among the highest reported for an incretin.
- Heart rate. As with other incretin agonists, modest heart rate increases have been observed; long-term cardiovascular effects are the subject of dedicated Phase III trials.
- Storage. Lyophilized peptide is best stored refrigerated and protected from light. Once reconstituted, refrigerate and use within the stability window specified by the supplier.
Sources
- 1.le Roux CW et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
- 2.Blüher M et al. (2024). Dose-response effects of the glucagon/GLP-1 receptor co-agonist survodutide on bodyweight and glycaemic control in people with type 2 diabetes: a phase 2 trial. Diabetologia.
- 3.Sanyal AJ et al. (2024). Phase 2 Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine.
- 4.Thomas L et al. (2024). Pharmacological characterization of survodutide, a glucagon/glucagon-like peptide-1 receptor co-agonist. Diabetes, Obesity and Metabolism.